Cargando…

Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial

BACKGROUND: Kawasaki disease (KD) is an acute systemic vasculitis of unclear etiology that mainly affects infants and young children. Strategies to reduce the incidence and severity of coronary artery lesions (CALs), the determinant factor in the long-term prognosis of KD, are currently a focus of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Si-Yuan, He, Lan, Xie, Li-Ping, Wang, Yin, Lin, Yi-Xiang, Cao, Yin-Yin, Yan, Wei-Li, Liu, Fang, Huang, Guo-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665612/ https://www.ncbi.nlm.nih.gov/pubmed/34895290 http://dx.doi.org/10.1186/s13063-021-05807-3

Ejemplares similares

High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone
por: Goto, Masahiro, et al.
Publicado: (2015)

Single serum cortisol values at 09:00 h can be indices of adrenocortical function in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone
por: Goto, Masahiro, et al.
Publicado: (2015)

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Ma, Yongmei, et al.
Publicado: (2022)

Retracted: Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
por: Aoyagi, Reiko, et al.
Publicado: (2015)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol
por: Eleftheriou, Despina, et al.
Publicado: (2023)

Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial
por: Wang, Yilong, et al.
Publicado: (2019)

Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease
por: Xie, Tian, et al.
Publicado: (2017)

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment
por: Ko, Tai-Ming, et al.
Publicado: (2018)

Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
por: Li, Wei, et al.
Publicado: (2022)

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial
por: Zhang, Haiyan, et al.
Publicado: (2023)

Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease
por: Lee, Hye Young, et al.
Publicado: (2016)

Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
por: Hur, Gyu, et al.
Publicado: (2018)

Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study
por: Nanishi, Etsuro, et al.
Publicado: (2017)

Could Immunoglobulin Level Be a Prognostic Factor for Coronary Artery Lesions in Kawasaki Diseases?
por: Han, Mi Young
Publicado: (2021)

Prednisolone Suppresses the Extracellular Release of HMGB-1 and Associated Inflammatory Pathways in Kawasaki Disease
por: Ueno, Kentaro, et al.
Publicado: (2021)

Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023)

Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease
por: Lu, Yaheng, et al.
Publicado: (2021)

Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
por: Mori, Masaaki, et al.
Publicado: (2018)

Prognosis and Risk Factors of Coronary Artery Lesions before Immunoglobulin Therapy in Children with Kawasaki Disease
por: Qiu, Huixian, et al.
Publicado: (2020)

Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease
por: He, Lan, et al.
Publicado: (2021)

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
por: Yu, Hun-Ju, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial
por: Liao, Yan Biao, et al.
Publicado: (2021)

Factors Predicting Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Lesion in Patients with Kawasaki Disease: Analysis of the Korean Nationwide Multicenter Survey from 2012 to 2014
por: Kim, Min Kyu, et al.
Publicado: (2017)

Early Immunoglobulin Therapy and Outcomes in Kawasaki Disease: A Nationwide Cohort Study
por: Ho, Chi-Lin, et al.
Publicado: (2015)

Sonographic Gallbladder Abnormality Is Associated with Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Chen, Chih-Jen, et al.
Publicado: (2012)

GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial
por: Cryer, Byron, et al.
Publicado: (2013)

Comparison of the Laboratory Data Between Kawasaki Disease and Enterovirus After Intravenous Immunoglobulin Treatment
por: Lin, Li-Yan, et al.
Publicado: (2012)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
por: Izumi, Kouji, et al.
Publicado: (2022)

Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?—Current evidence based on a meta-analysis
por: Zheng, Xiaolan, et al.
Publicado: (2021)

Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial
por: Li, Li, et al.
Publicado: (2018)

Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial
por: Hall, Peter, et al.
Publicado: (2015)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin
por: Galeotti, Caroline, et al.
Publicado: (2010)

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
por: Nadig, Pallavi L., et al.
Publicado: (2023)

Unsuccessful Cyclosporine plus Prednisolone Therapy for Autoimmune Meningoencephalitis in Three Dogs
por: JUNG, Dong-In, et al.
Publicado: (2013)

Clinically Useful Predictors of Resistance to Intravenous Immunoglobulin and Prognosis of Coronary Artery Lesions in Patients with Incomplete Kawasaki Disease
por: Cho, Kee Hyun, et al.
Publicado: (2014)

C-Reactive Protein to Albumin Ratio for Predicting Coronary Artery Lesions and Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Tsai, Chih-Min, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_du1bi1tlktab5vahf5hv1a2kem